PERTH, Australia – More money will be deployed in Australia's life sciences sector in the next four or five years than there has ever been, according to Australia's biggest life sciences investor.
PERTH, Australia – In yet another regional carve-out deal for Starpharma Holdings Ltd., the company has out-licensed rights to its Vivagel BV for bacterial vaginosis (BV) to ITF Pharma for the U.S. market for roughly $101 million.
PERTH, Australia – Australia's Sonic Healthcare Ltd. is significantly expanding its U.S. footprint with the acquisition of Aurora Diagnostics LLC, of Palm Beach Gardens, Fla., for A$750 million (US$540 million) in an all-cash deal. About 90 percent of Aurora's revenue comes from its anatomical pathology services, and Sonic has deep roots in the anatomical pathology market. The acquisition extends Sonic's existing presence in anatomical pathology, which is a fragmented market in the U.S.
Australian radiopharma company Telix Pharmaceuticals Ltd. announced it is acquiring its partner, Belgium-based Advanced Nuclear Medicine Ingredients (Anmi) SA, for roughly A$8.1 million (US$5.9 million) in cash and Telix shares. The move accelerates commercialization of Telix's prostate cancer diagnostic kit, Illumet, in the U.S. and Europe.
Australian radiopharma company Telix Pharmaceuticals Ltd. announced it is acquiring its partner, Belgium-based Advanced Nuclear Medicine Ingredients (Anmi) SA, for roughly A$8.1 million (US$5.9 million) in cash and Telix shares. The move accelerates commercialization of Telix's prostate cancer diagnostic kit, Illumet, in the U.S. and Europe.
